‘‘(2) AWARDS.—In making awards under para-
graph (1), the Secretary shall— 
‘‘(A) ensure that information provided 
through demonstration projects supported by 
such an award is consistent with the best avail-
able medical information; and 
‘‘(B) give preference to— 
‘‘(i) applicants with demonstrated ex-
pertise in— 
‘‘(I) biomarker testing and clin-
ical trials in brain tumors and other 
recalcitrant cancers; 
‘‘(II) brain cancer and other re-
calcitrant cancer education or treat-
ment; 
‘‘(III) working with groups of pa-
tients and caregivers; and 
‘‘(IV) reaching geographic areas 
that have historically low rates of par-
ticipation in cancer clinical trials; and 
‘‘(ii) applicants that demonstrate in 
their application submitted under para-
graph (3) that the project for which they 
are seeking a grant or contract will involve 
and connect physicians, nurses, other key 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
health professionals, health profession stu-
dents, hospitals, and payers. 
‘‘(3) APPLICATIONS.—To seek a grant or con-
tract under this subsection, an entity shall submit 
an application to the Secretary in such form, in such 
manner, and containing such agreements, assur-
ances, and information as the Secretary may reason-
ably require. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there is authorized 
to be appropriated $10,000,000 for the period of fiscal 
years 2026 through 2030.’’. 
SEC. 6. PILOT PROGRAMS TO DEVELOP, STUDY, OR EVALU-
ATE APPROACHES TO MONITORING AND CAR-
ING FOR BRAIN TUMOR SURVIVORS. 
Part B of title IV of the Public Health Service Act 
(42 U.S.C. 284 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 409K. PILOT PROGRAMS TO DEVELOP, STUDY, OR 
EVALUATE APPROACHES TO MONITORING 
AND CARING FOR BRAIN TUMOR SURVIVORS. 
‘‘(a) IN GENERAL.—The Director of NIH may, as 
appropriate, make awards to eligible entities to establish 
pilot programs to develop, study, or evaluate approaches, 
including primary care, for monitoring and caring for 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
adult and pediatric brain tumor survivors throughout their 
lifespan, including evaluating models for transition to 
post-treatment care and care coordination. 
‘‘(b) AWARDS.— 
‘‘(1) ELIGIBLE ENTITIES.— 
‘‘(A) IN GENERAL.—For purposes of this 
section, an eligible entity is— 
‘‘(i) a medical school; 
‘‘(ii) a children’s hospital; 
‘‘(iii) a cancer center; 
‘‘(iv) a community-based medical facil-
ity; or 
‘‘(v) any other entity with significant 
experience and expertise in carrying out 
the activities described in subsection (a). 
‘‘(B) TYPES OF ENTITIES.—Awards under 
this section shall be made, to the extent prac-
tical, to— 
‘‘(i) small, medium, and large-sized el-
igible entities; and 
‘‘(ii) sites located in different geo-
graphic areas, including rural and urban 
areas. 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(2) PEER REVIEW.—In making awards under 
this section, the Director of NIH shall comply with 
the peer review requirements in section 492. 
‘‘(3) USE
OF
FUNDS.—Funds from awards 
under this section may be used to develop, study, or 
evaluate one or more models for monitoring and car-
ing for brain tumor survivors, which may include— 
‘‘(A) evaluating follow-up care, educational 
accommodations, monitoring, and other survi-
vorship programs (including peer support and 
mentoring programs); 
‘‘(B) developing and evaluating models for 
providing multidisciplinary care; 
‘‘(C) disseminating information to health 
care providers about culturally and linguistically 
appropriate follow-up care for brain tumor sur-
vivors and their families, as appropriate and 
practicable; 
‘‘(D) developing and evaluating existing 
psychosocial evaluations, counseling, and sup-
port programs to improve the quality of life of 
brain tumor survivors and their families, which 
may include peer support and mentoring pro-
grams; 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(E) designing and evaluating tools to sup-
port the secure electronic transfer of treatment 
information and care summaries from brain 
tumor care providers to other health care pro-
viders (including primary care providers), which 
information and care summaries shall include 
risk factors and a plan for recommended follow- 
up care; 
‘‘(F) developing and evaluating initiatives 
that promote the coordination and effective 
transition of care between brain tumor care 
providers, primary care providers, mental health 
professionals, and other health care profes-
sionals, as appropriate, including models that 
use a team-based or multi-disciplinary approach 
to care; and 
‘‘(G) disseminating information described 
in subparagraphs (A) through (F), including 
with respect to models, evaluations, programs, 
systems, and initiatives described in such sub-
paragraphs, to other health care providers (in-
cluding primary care providers) and to pediatric 
brain tumor survivors and their families, where 
appropriate and in accordance with Federal and 
State law. 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
$5,000,000 for each of fiscal years 2026 through 2030.’’. 
SEC. 7. FDA GUIDANCE TO ENSURE BRAIN TUMOR PATIENT 
ACCESS TO CLINICAL TRIALS. 
Not later than 1 year after the date of enactment 
of this Act, the Secretary of Health and Human Services, 
acting through the Commissioner of Food and Drugs, 
shall issue guidance to help identify ways to minimize the 
potential for the exclusion of brain tumor patients and pa-
tients with rare and recalcitrant cancers from clinical 
trials evaluating treatments for other indications. 
Æ 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6301
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB